Objective
to report the 3-year clinical outcomes of TAVI compared to SAVR for the treatment of severe aortic stenosis in younger patients with low surgical risk
Study
investigator-initiated, multicentre, randomised controlled trial (1:1 ratio)
Population
patients aged ≤75 with severe tricuspid or bicuspid aortic stenosis scheduled for bioprosthetic aortic valve replacement with low estimated 30-day surgical mortality risk (STS score <4%)
Endpoints
composite of death, stroke, or rehospitalisation related to the procedure, valve, or heart failure at 3 years
Conclusion
In younger patients with severe aortic stenosis at low surgical risk, no significant differences were observed between TAVR and surgery in relation to individual endpoints at 3 years. Both procedures are associated with low rates of structural valve deterioration and need for reintervention.
Jorgensen et al. Circulation. 2025 Nov 11.